Posts

Reditus ‘on the front lines in the fight against cancer

Reditus Laboratories is excited to bring on our first biomarker as we move to the forefront of malignancy and precision pathology. The test will determine whether patients with certain cancers are good candidates for a specific cancer treatment and soon will be available at Reditus.

Reditus Labs keeping up with COVID-19 test processing turnaround despite increased demand, staffing challenges

PEKIN, IL – Increased demand for nasal swab COVID-19 tests isn’t impacting test result turnaround time, so far. Dr. Aaron Rossi, CEO of Reditus Laboratories[…]

PATHOLOGY LAB TRANSFORMS, RUNS 1M COVID-19 TESTS

Histopathology lab adapts its molecular capabilities to handle ever-greater numbers of SARS-CoV-2 tests By Robert Michel| From The Dark Report Volume XXVIII No. 3 – March 1, 2021 Issue CEO SUMMARY: Last spring, a histopathology lab in Illinois began running molecular COVID-19 tests and decided the clinical side of the lab would focus exclusively on PCR testing […]